Insmed Presents Positive Data on Anti-Cancer Drug Candidate to
2003-12-03 15:15 (New York)
San Antonio Breast Cancer Symposium
Health/Medical Writers / Business Editors
BIOWIRE2K
RICHMOND, Va.--(BUSINESS WIRE)--Dec. 3, 2003
Study Shows rhIGFBP-3 Enhances Sensitivity to Herceptin(R)
(Trastuzumab) in Models of Herceptin(R) Resistant Breast Cancer
Insmed Incorporated (Nasdaq-NMS: INSM) (Nasdaq: INSM) reported
today that data from recent studies of the Company's proprietary
anti-cancer compound, recombinant human insulin-like growth factor
binding protein-3 (rhIGFBP-3), will be presented at The 26th Annual
San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry
B. Gonzalez Convention Center, San Antonio, Texas, December 3 - 6.
These studies conducted in the laboratory of Dr. Brian
Leyland-Jones of McGill University were designed to explore the
ability of rhIGFBP-3 to sensitize breast cancer cells to Herceptin(R)
(Trastuzumab).
The results of this study, published in the abstract titled,
"Recombinant human insulin-like growth factor binding protein-3
(rhIGFBP-3) as a potential therapeutic agent for the treatment of
Herceptin-resistant breast cancer", demonstrated the following:
1. In Herceptin resistant breast carcinoma cells there was an
increased level of insulin-like growth factor receptor.
2. rhIGFBP-3 caused dose dependent inhibition of Herceptin
resistant breast carcinoma growth.
3. rhIGFBP-3 in combination with Herceptin caused a dose dependent
increase in sensitivity of breast carcinoma cells to Herceptin.
Please view the abstract and poster being presented:
1. Go to www.insmed.com
2. Click on "Product Pipeline"
3. Click on the cancer development timeline arrow
For reprints, please contact, Baxter Phillips, at 804.565.3041 or
bphillips@insmed.com.
IGFBP-3: A Naturally Occurring Anti-Cancer Agent
Our proprietary product, rhIGFBP-3, is a protein that is normally
found in our bloodstream that has been shown to induce cancer cell
death in a variety of experimental systems. Several studies have
demonstrated that cancer risk increases with decreasing levels of
circulating IGFBP-3. In addition, recent independent studies have
demonstrated that IGFBP-3 can induce cell cycle arrest and enhance the
efficacy of chemotherapeutic agents. Insmed is currently engaged in an
active preclinical program with leading clinical oncologists and world
experts in the field of IGFBP-3 research to evaluate the efficacy of
rhIGFBP-3 as a therapeutic agent and to define the optimal clinical
protocol in which to translate these promising observations into human
clinical trials.
About Insmed
Insmed Incorporated develops pharmaceutical products for the
treatment of metabolic and endocrine diseases with unmet medical
needs. The Company's most advanced product candidate, the
rhIGF-I/rhIGFBP-3 complex is a novel delivery composition of IGF-I
that regulates essential metabolic and anabolic (growth promoting)
processes, such as glucose uptake and tissue regeneration. Insmed is
currently in a pivotal Phase III clinical trial for the
rhIGF-I/rhIGFBP-3 complex for the treatment of Growth Hormone
Insensitivity Syndrome (GHIS). The Company's second product candidate,
rhIGFBP-3, is a recombinant protein that is being developed as an
anti-cancer agent targeted towards the inhibition of solid tumor
growth. Further information is available at the company's corporate
website: www.insmed.com
About Herceptin(R)
Herceptin(R) is the first humanized antibody approved for the
treatment of HER2 positive metastatic breast cancer. Herceptin(R) is
designed to target and block the function of HER2 protein
overexpression. Herceptin(R) is a registered trademark of Genentech
(NYSE: DNA). |
